title: Is the use of letrozole to induce ovulation teratogenic?
abstract: OBJECTIVE
  A patient of mine has been prescribed letrozole to induce ovulation; however, a recent release from the Food and Drug Administration contraindicates the use of letrozole in premenopausal women owing to teratogenicity. Does the use of letrozole increase the risk of a child being born with a birth defect?
  
  
  CONCLUSIONS
  The use of letrozole to induce ovulation has not been associated with an increased risk of a child being born with a birth defect; in contrast, the use of clomiphene citrate in pregnancy is associated with intrauterine growth restriction.
authors.forename: Simerpal Kaur
authors.initials: SK
authors.lastname: Gill
authors.forename: Myla
authors.initials: M
authors.lastname: Moretti
authors.forename: Gideon
authors.initials: G
authors.lastname: Koren
mesh_terms: D000014:Abnormalities, Drug-Induced; D000818:Animals; D047072:Aromatase Inhibitors / Q000009:adverse effects*; D005260:Female; D005300:Fertility Agents, Female / Q000009:adverse effects*; D006801:Humans; D000077289:Letrozole; D009570:Nitriles / Q000009:adverse effects*; D010062:Ovulation Induction / Q000379:methods*; D011247:Pregnancy; D011256:Pregnancy Outcome; D012306:Risk; D014230:Triazoles / Q000009:adverse effects*
chemical_list: D047072:Aromatase Inhibitors; D005300:Fertility Agents, Female; D009570:Nitriles; D014230:Triazoles; D000077289:Letrozole